3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg; Anke H Maitland-van der Zee; Guy Brusselle; Giorgio Walter Canonica; Alvar Agusti; Rosa Faner; Claus F Vogelmeier; Martijn Nawijn; Maarten van den Berge; Franca Rusconi; Charles Pilette; Valeria Ramiconi; Courtney Coleman; Rekha Chaudhuri; Kian Fan Chung; Jadwiga Wedzicha; Sejla Saglani; Marc P Van der Schee; Liam Heaney; Arnaud Bourdin; Graham Roberts; Ratko Djukanovic; Piotr Kuna; Maceij Kupczyk; Judith Axmann; Heribert Staudinger; Graham W Clarke; Sven Erik Dahlen; Chris Brightling

doi:10.1183/13993003.02168-2021

3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg, Anke H Maitland-van der Zee, Guy Brusselle, Giorgio Walter Canonica, Alvar Agusti, Rosa Faner, Claus F Vogelmeier, Martijn Nawijn, Maarten van den Berge, Franca Rusconi, Charles Pilette, Valeria Ramiconi, Courtney Coleman, Rekha Chaudhuri, Kian Fan Chung, Jadwiga Wedzicha, Sejla Saglani, Marc P Van der Schee, Liam Heaney, Arnaud BourdinGraham Roberts, Ratko Djukanovic, Piotr Kuna, Maceij Kupczyk, Judith Axmann, Heribert Staudinger, Graham W Clarke, Sven Erik Dahlen, Chris Brightling

Research output: Contribution to journal › Article › peer-review

Abstract

The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.

Original language	English
Article number	2102168
Journal	European Respiratory Journal
Volume	58
Issue number	4
DOIs	https://doi.org/10.1183/13993003.02168-2021
Publication status	Published - 21 Oct 2021

Keywords

Cross-Sectional Studies
Pulmonary Disease, Chronic Obstructive - drug therapy
Humans
Asthma - drug therapy

Access to Document

10.1183/13993003.02168-2021Licence: Unspecified

Cite this

Porsbjerg, C., Maitland-van der Zee, A. H., Brusselle, G., Canonica, G. W., Agusti, A., Faner, R., Vogelmeier, C. F., Nawijn, M., van den Berge, M., Rusconi, F., Pilette, C., Ramiconi, V., Coleman, C., Chaudhuri, R., Chung, K. F., Wedzicha, J., Saglani, S., Van der Schee, M. P., Heaney, L., ... Brightling, C. (2021). 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 58(4), [2102168]. https://doi.org/10.1183/13993003.02168-2021

@article{e7aaa9df0d7e4d47a1435c08cf1b7a20,

title = "3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD",

abstract = "The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.",

keywords = "Cross-Sectional Studies, Pulmonary Disease, Chronic Obstructive - drug therapy, Humans, Asthma - drug therapy",

author = "Celeste Porsbjerg and {Maitland-van der Zee}, {Anke H} and Guy Brusselle and Canonica, {Giorgio Walter} and Alvar Agusti and Rosa Faner and Vogelmeier, {Claus F} and Martijn Nawijn and {van den Berge}, Maarten and Franca Rusconi and Charles Pilette and Valeria Ramiconi and Courtney Coleman and Rekha Chaudhuri and Chung, {Kian Fan} and Jadwiga Wedzicha and Sejla Saglani and {Van der Schee}, {Marc P} and Liam Heaney and Arnaud Bourdin and Graham Roberts and Ratko Djukanovic and Piotr Kuna and Maceij Kupczyk and Judith Axmann and Heribert Staudinger and Clarke, {Graham W} and Dahlen, {Sven Erik} and Chris Brightling",

year = "2021",

month = oct,

day = "21",

doi = "10.1183/13993003.02168-2021",

language = "English",

volume = "58",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "EUROPEAN RESPIRATORY SOC JOURNALS LTD",

number = "4",

}

Porsbjerg, C, Maitland-van der Zee, AH, Brusselle, G, Canonica, GW, Agusti, A, Faner, R, Vogelmeier, CF, Nawijn, M, van den Berge, M, Rusconi, F, Pilette, C, Ramiconi, V, Coleman, C, Chaudhuri, R, Chung, KF, Wedzicha, J, Saglani, S, Van der Schee, MP, Heaney, L, Bourdin, A, Roberts, G, Djukanovic, R, Kuna, P, Kupczyk, M, Axmann, J, Staudinger, H, Clarke, GW, Dahlen, SE & Brightling, C 2021, '3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD', European Respiratory Journal, vol. 58, no. 4, 2102168. https://doi.org/10.1183/13993003.02168-2021

TY - JOUR

T1 - 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

AU - Porsbjerg, Celeste

AU - Maitland-van der Zee, Anke H

AU - Brusselle, Guy

AU - Canonica, Giorgio Walter

AU - Agusti, Alvar

AU - Faner, Rosa

AU - Vogelmeier, Claus F

AU - Nawijn, Martijn

AU - van den Berge, Maarten

AU - Rusconi, Franca

AU - Pilette, Charles

AU - Ramiconi, Valeria

AU - Coleman, Courtney

AU - Chaudhuri, Rekha

AU - Chung, Kian Fan

AU - Wedzicha, Jadwiga

AU - Saglani, Sejla

AU - Van der Schee, Marc P

AU - Heaney, Liam

AU - Bourdin, Arnaud

AU - Roberts, Graham

AU - Djukanovic, Ratko

AU - Kuna, Piotr

AU - Kupczyk, Maceij

AU - Axmann, Judith

AU - Staudinger, Heribert

AU - Clarke, Graham W

AU - Dahlen, Sven Erik

AU - Brightling, Chris

PY - 2021/10/21

Y1 - 2021/10/21

N2 - The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.

AB - The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.

KW - Cross-Sectional Studies

KW - Pulmonary Disease, Chronic Obstructive - drug therapy

KW - Humans

KW - Asthma - drug therapy

U2 - 10.1183/13993003.02168-2021

DO - 10.1183/13993003.02168-2021

M3 - Article

C2 - 34675035

VL - 58

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 4

M1 - 2102168

ER -

3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Abstract

Keywords

Access to Document

Fingerprint

Cite this